Side-effects of non-steroidal anti-inflammatory drugs in children with juvenile rheumatoid arthritis

1987 ◽  
pp. 125-135
Author(s):  
T. K. Kvien ◽  
H. M. Høyeraal ◽  
B. Sandstad ◽  
E. Kåss
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Juvenile Rheumatoid Arthritis ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Effect on lung function of methotrexate and non-steroid anti-inflammatory drugs in children with juvenile rheumatoid arthritis

1998 ◽  
Vol 18 (1) ◽  
pp. 11-16 ◽  
Author(s):  
G. Camiciottoli ◽  
S. Trapani ◽  
W. Castellani ◽  
R. Ginanni ◽  
M. Ermini ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Lung Function ◽  
Juvenile Rheumatoid Arthritis ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Flufenamic Acid and Placebo Compared in Rheumatoid Arthritis and Osteoarthritis

1981 ◽  
Vol 9 (4) ◽  
pp. 253-256 ◽  
Author(s):  
G Kagan ◽  
L Huddlestone ◽  
P Wolstencroft
Keyword(s):  
Rheumatoid Arthritis ◽  
General Practice ◽  
Side Effects ◽  
Crossover Study ◽  
Morning Stiffness ◽  
Flufenamic Acid ◽  
Moderate Pain ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Forty patients in general practice with rheumatoid arthritis or osteoarthritis were identified as suffering from moderate pain and tenderness and moderate stiffness in excess of 30 minutes. After discontinuation of non-steroidal anti-inflammatory drugs for 2 weeks, a crossover study was conducted comparing the benefits of flufenamic acid, 100 mg, four times daily with placebo. At the same time, paracetamol at a dose up to 8 × 500 mg daily, could be used for pain which the patient judged to be unrelieved. Thirty-four patients completed the two 3-week test periods and twenty-one patients were improved in relation to morning stiffness and pain by flufenamic acid and twelve patients by placebo – a difference greater than would have occurred by chance (p = 0.05). At the same time, paracetamol consumption was reduced significantly from a mean of 91.29 tablets to 60.68 tablets for each 3-week period. Side-effects occurred in ten patients on placebo and fifteen patients on flufenamic acid. One patient on each medication had to discontinue for multiple side-effects. Diarrhoea occurred in two patients on flufenamic acid and in one patient on placebo. Flufenamic acid is clearly effective and side-effects do not occur more often than would be expected by chance when compared with placebo.

EVENING PRIMROSE OIL IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SIDE-EFFECTS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

Rheumatology ◽  
1991 ◽  
Vol 30 (5) ◽  
pp. 370-372 ◽  
Author(s):  
M. BRZESKI ◽  
R. MADHOK ◽  
H. A. CAPELL
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Evening Primrose Oil ◽  
Evening Primrose ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

The choice of non-steroidal anti-inflammatory drugs in the rheumatic diseases

1977 ◽  
Vol 15 (24) ◽  
pp. 93-95
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Rheumatic Diseases ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Since we discussed drugs for the treatment of rheumatoid arthritis in 19751 still more preparations of non-steroidal anti-inflammatory agents have been introduced. Any new preparation has to be compared with established ones, and so far none of the newer anti-inflammatory preparations has proved clearly superior, in either efficacy or freedom from side effects, to aspirin or indomethacin. But as many patients do not tolerate these two standard drugs, alternatives are often needed. This article discusses the choice between the alternative anti-inflammatory drugs listed in Table I.

Risks of Cardiovascular Disease and Beyond in Prescription of Nonsteroidal Anti-Inflammatory Drugs

2019 ◽  
Vol 25 (1) ◽  
pp. 3-6 ◽  
Author(s):  
Manas A. Rane ◽  
Alexander Gitin ◽  
Benjamin Fiedler ◽  
Lawrence Fiedler ◽  
Charles H. Hennekens
Keyword(s):  
Cardiovascular Disease ◽  
Side Effects ◽  
Health Care Providers ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Care Providers ◽  
Relieve Pain ◽  
Gastrointestinal Side Effects ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) include aspirin, naproxen, diclofenac, and ibuprofen, as well as selective cyclooxygenase 2 inhibitors such as celecoxib. Their use is common, as well as their side effects which cause 100 000 hospitalizations and 17 000 deaths annually. Recently, the US Food and Drug Administration strengthened its warning about the risks of cardiovascular disease (CVD) attributed to nonaspirin NSAIDs. Methods: When the sample size is large, randomization provides control of confounding not possible to achieve with any observational study. Further, observational studies and, especially, claims data have inherent confounding by indication larger than the small to moderate effects being sought. Results: While trials are necessary, they must be of sufficient size and duration and achieve high compliance and follow-up. Until then, clinicians should remain uncertain about benefits and risks of these drugs. Conclusions: Since the totality of evidence remains incomplete, health-care providers should consider all these aforementioned benefits and risks, both CVD and beyond, in deciding whether and, if so, which, NSAID to prescribe. The factors in the decision of whether and, if so, which NSAID to prescribe for relief of pain from inflammatory arthritis should not be limited to risks of CVD or gastrointestinal side effects but should also include potential benefits including improvements in overall quality of life resulting from decreases in pain or impairment from musculoskeletal pain syndromes. The judicious individual clinical decision-making about the prescription of NSAIDs to relieve pain based on all these considerations has the potential to do much more good than harm.

Sign in / Sign up

Export Citation Format

Share Document